For manufacturers, this presents a dilemma
This applies whether you are moving: from Wegovy (semaglutide) to Mounjaro (tirzepatide) , or from Mounjaro (tirzepatide) to Wegovy (semaglutide) This balances safety and practicality: it gives sufficient time for most of the prior drugs activity to decrease, helping to reduce the risk of overlapping effects and side effects
They provide the biological support that was missing for so long, making sustainable change feel achievable for the first time for many people
Its clinical program in the late 2000s was built around large, rigorously controlled trials with a hard imaging endpoint (visceral adipose tissue measured by CT), and it culminated in FDA approval in 2010
2 CagriSema is not approved in the US or EU
Our individualized recovery strategies help patients recover quickly to reach their best health status